NEWS
Clearside Biomedical Partner Arctic Vision Executes Commercial Collaboration Agreement with Santen Pharmaceutical Co., Ltd for ARVN001 Suprachoroidal Space Injection Therapy for the Treatment of Uveitic Macular Edema
Clearside Biomedical (CLSD) announced that its Asia-Pacific partner, Arctic Vision, has signed a commercial collaboration agreement with Santen Pharmaceutical for ARVN001 (branded as XIPERE® in the US) for treating uveitic macular edema in China. Under the agreement, Arctic Vision grants Santen rights to commercialize ARVN001 in mainland China. The partnership validates Clearside's suprachoroidal delivery platform, which is now being utilized by major pharmaceutical companies including Santen, Bausch + Lomb, AbbVie, REGENXBIO, Aura Biosciences, and BioCryst. Arctic Vision recently reported positive Phase 3 trial results in China and has regulatory reviews ongoing in Australia and Singapore.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2951Followers
109Following
31KVisitors
Follow